{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:10:10Z","timestamp":1791353410075,"version":"4.3.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FRIAT"},{"DOI":"10.13039\/100018504","name":"Nipro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSL Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current guidelines establish the same hemoglobin (Hb) and iron biomarkers targets for hemodialysis (HD) and peritoneal dialysis (PD) in patients receiving erythropoiesis-stimulating agents (ESAs) even though patients having PD are usually younger, more active and less comorbid. Unfortunately, specific renal anemia [anemia in chronic kidney disease (aCKD)] trials or observational studies on PD are scanty. The aims of this study were to describe current aCKD management, goals and adherence to clinical guidelines, identifying opportunities for healthcare improvement in PD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, nationwide, multicentre study including patients from 19 PD units. The nephrologists collected baseline data, demographics, comorbidities and data related to anemia management (laboratory values, previously prescribed treatments and subsequent adjustments) from electronic medical records. The European adaptation of KDIGO guidelines was the reference for definitions, drug prescriptions and targets.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 343 patients (mean age 62.9\u00a0years, 61.2% male) were included; 72.9% were receiving ESAs and 33.2% iron therapy [20.7% intravenously (IV)]. Eighty-two patients were receiving ESA without iron therapy, despite 53 of them having an indication according to the European Renal Best Practice guidelines. After laboratory results, iron therapy was only started in 15% of patients. Among ESA-treated patients, 51.9% had an optimal control [hemoglobin (Hb) 10\u201312\u00a0g\/dL] and 28.3% between 12\u201312.9\u00a0g\/dL. Seventeen patients achieved Hb &amp;gt;13\u00a0g\/dL, and 12 of them remained on ESA after overshooting. Only three patients had Hb &amp;lt;10\u00a0g\/dL without ESAs. Seven patients (2%) met criteria for ESA resistance (epoetin dose &amp;gt;300\u00a0IU\/kg\/week). The highest tertile of erythropoietin resistance index (&amp;gt;6.3 UI\/kg\/week\/g\/dL) was associated with iron deficiency and low albumin corrected by renal replacement therapy vintage and hospital admissions in the previous 3\u00a0months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Iron therapy continues to be underused (especially IV). Low albumin, iron deficiency and prior events explain most of the ESA hyporesponsiveness. Hb targets are titrated to\/above the upper limits. Thus, several missed opportunities for adequate prescriptions and adherence to guidelines were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfad152","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:50:28Z","timestamp":1688089828000},"page":"2493-2502","source":"Crossref","is-referenced-by-count":15,"title":["Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-1385","authenticated-orcid":false,"given":"Jose","family":"Portoles","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , IDIPHISA, Madrid , Spain"},{"name":"Anemia Working Group of the Spanish Society of Nephrology , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Serrano Salazar","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda , IDIPHISA, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gonz\u00e1lez Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Basurto, Bilbao , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gallego Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario San Pedro de Alc\u00e1ntara, C\u00e1ceres , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-7235","authenticated-orcid":false,"given":"Manel","family":"Vera Rivera","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Clinic , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jara","family":"Caro Espada","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Doce de Octubre, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Herreros Garc\u00eda","sequence":"additional","affiliation":[{"name":"Nephrology Department, Fundaci\u00f3n Puigvert, Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Munar Vila","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Son Espases, Mallorca , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jos\u00e9 Espigares Huete","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Virgen de las Nieves, Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-0819","authenticated-orcid":false,"given":"Haridian","family":"Sosa Barrios","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Para\u00edso","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Henares, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Mariscal de Gante","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario de la Princesa, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Auxiliadora","family":"Bajo","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia Gueorguieva","family":"Mijaylova","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1on, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pascual Pajares","sequence":"additional","affiliation":[{"name":"Nephrology Department, Complejo Hospital Universitario de Toledo, Toledo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Areste Fosalba","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Virgen de la Macarena, Sevilla , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Espinel","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario de Getafe. Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tornero Molina","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Sureste, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Pizarro S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Rey Juan Carlos, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Ortega D\u00edaz","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Infanta Leonor, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-8184","authenticated-orcid":false,"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[{"name":"Anemia Working Group of the Spanish Society of Nephrology , Spain"},{"name":"Nephrology Department, Hospital Clinic , Barcelona , Spain"},{"name":"Medicine Department, Universitat de Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-1929","authenticated-orcid":false,"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[{"name":"Anemia Working Group of the Spanish Society of Nephrology , Spain"},{"name":"IIS-La Princesa, Nephrology Department, Hospital Universitario de la Princesa , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"2023120101570381300_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2023120101570381300_bib2","doi-asserted-by":"crossref","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023120101570381300_bib3","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"2023120101570381300_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2019","journal-title":"Clin Kidney J"},{"key":"2023120101570381300_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023120101570381300_bib6","article-title":"Epidemiology and treatment of renal anemia in Spain: RIKAS retrospective study","author":"Cases","year":"2022;","journal-title":"Nefrologia"},{"key":"2023120101570381300_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s41669-019-0132-5","article-title":"Economic burden and health-related quality of life associated with current treatments for anemia in patients with CKD not on dialysis: a systematic review","volume":"3","author":"Pergola","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"2023120101570381300_bib8","doi-asserted-by":"crossref","first-page":"7692376","DOI":"10.1155\/2020\/7692376","article-title":"The impact of CKD anemia on patients: incidence, risk factors, and clinical outcomes-a systematic literature review","volume":"2020","author":"Palaka","year":"2020","journal-title":"Int J Nephrol"},{"key":"2023120101570381300_bib9","first-page":"140","article-title":"Implementation of clinical guidelines and compliance with target hemoglobin levels in peritoneal dialysis","volume":"33","author":"Portol\u00e9s","year":"2013","journal-title":"Nefrologia"},{"key":"2023120101570381300_bib10","first-page":"279","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"McMurray","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2023120101570381300_bib11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2023120101570381300_bib12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2023120101570381300_bib13","first-page":"2071","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume-title":"N Engl J Med","author":"Dr\u00fceke","year":"2006"},{"key":"2023120101570381300_bib14","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2023120101570381300_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023120101570381300_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2023120101570381300_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3747\/pdi.2018.00249","article-title":"International anemia prevalence and management in peritoneal dialysis patients","volume":"39","author":"Perlman","year":"2019","journal-title":"Perit Dial Int"},{"key":"2023120101570381300_bib18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2023120101570381300_bib19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","article-title":"Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale","volume":"67","author":"Ratcliffe","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2023120101570381300_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.kint.2016.03.036","article-title":"An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients","volume":"90","author":"Barbieri","year":"2016","journal-title":"Kidney Int"},{"key":"2023120101570381300_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semnephrol.2018.05.010","article-title":"Personalized anemia management and precision medicine in ESA and iron pharmacology in end-stage kidney disease","volume":"38","author":"Brier","year":"2018","journal-title":"Semin Nephrol"},{"key":"2023120101570381300_bib22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2023120101570381300_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"2023120101570381300_bib24","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2023120101570381300_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2008.05.029","article-title":"Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis","volume":"52","author":"Streja","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2023120101570381300_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2014.179","article-title":"ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target","volume":"86","author":"Hung","year":"2014","journal-title":"Kidney Int"},{"key":"2023120101570381300_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ckj\/sfz153","article-title":"Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study","volume":"14","author":"Portol\u00e9s","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023120101570381300_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2023120101570381300_bib29","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD Study investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2023120101570381300_bib30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2023120101570381300_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.xkme.2020.06.008","article-title":"Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era","volume":"2","author":"Cizman","year":"2020","journal-title":"Kidney Med"},{"key":"2023120101570381300_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.2008.523","article-title":"Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality","volume":"74","author":"L\u00f3pez-G\u00f3mez","year":"2008","journal-title":"Kidney Int"},{"key":"2023120101570381300_bib33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12882-022-02969-3","article-title":"Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel","volume":"23","author":"Mazzaferro","year":"2022","journal-title":"BMC Nephrol"},{"key":"2023120101570381300_bib34","first-page":"316","article-title":"First episodes of peritoneal infection: description and prognostic factors","volume":"33","author":"Portol\u00e9s","year":"2013","journal-title":"Nefrologia"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad152\/51146786\/sfad152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/12\/2493\/53960098\/sfad152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/12\/2493\/53960098\/sfad152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T01:57:58Z","timestamp":1701395878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/12\/2493\/7210548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,29]]},"published-print":{"date-parts":[[2023,11,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad152","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,29]]}}}